Quantcast

Latest Tumor hypoxia Stories

2008-09-24 03:00:12

By Yeom, Chan Joo Chung, June-Key; Kang, Joo Hyun; Jeon, Yong Hyun; Kim, Kwang Il; Jin, Yong Nan; Lee, You Mie; Jeong, Jae Min; Lee, Dong Soo Hypoxia-inducible factor-1 (HIF-1) is a transcription factor of hypoxic response in cancer cells and is associated with tumor progression, angiogenesis, metastasis, and resistance to therapy. We assessed whether the human sodium iodide symporter (NIS) reporter systems can be used to visualize transcriptional activation of HIF- 1 in C6 glioma. Methods:...

2008-09-16 09:00:15

REDWOOD CITY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLDD), today announced that it has initiated a Phase 1/2 clinical trial of TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. "The treatment of soft tissue sarcomas continues to be a difficult challenge. New therapeutic and novel agents are required to improve the...

2008-08-12 09:00:38

REDWOOD CITY, Calif., Aug. 12, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a clinical trial of TH-302 in combination with various chemotherapeutic agents in patients with advanced solid tumors. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. "Targeting tumor hypoxia is an exciting area of cancer research, and may offer great promise to patients with a wide variety of cancers,"...

2008-08-06 09:00:11

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, today announced that a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") is scheduled for October to present the clinical development plan for a anti-hypoxia drug to be used in combination with DAVANAT(R) and 5-FU to treat advanced solid tumors, including head and neck, breast...

2008-07-24 09:01:14

REDWOOD CITY, Calif., July 24, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that Herbert Hurwitz, M.D. has joined the Company's Scientific Advisory Board (SAB). Dr. Hurwitz is an Associate Professor of Medicine at Duke University Medical Center and a medical oncologist at the Duke Comprehensive Cancer Center. "Tumor hypoxia is a promising area that is gaining a great deal of attention among the medical research community," said Herbert Hurwitz, M.D....

2008-07-15 09:00:16

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a biopharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to define the regimen for an Oxygen-based product (EZ-646) to be used with Galactomannan-C (DAVANAT(R)) and Fluorouracil (5-FU) to treat all solid tumors, including new indications such as head & neck and...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related